Late-stage atopic dermatitis treatment on target

With OC459, a first-in-class, oral, once-a-day small molecule for atopic dermatitis, Atopix has a potential winner for this and other type 2 helper T cell–mediated disorders such as severe asthma and related allergic conditions. To download the full article, please sign in.

Like
Page of
Go to the profile of Atopix Therapeutics Ltd

Atopix Therapeutics Ltd

Atopix Therapeutics Limited is a clinical stage biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma.

Comments are disabled